XML 67 R32.htm IDEA: XBRL DOCUMENT
v3.22.4

Collaboration Agreements - Additional Information (Details) $ in Thousands |  |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Aug. 17, 2021 USD ($) | Jul. 01, 2021 USD ($) | Jan. 31, 2022 USD ($) | Jan. 31, 2018 USD ($) | Oct. 31, 2017 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Feb. 28, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  | $ 444,900 | $ 307,900 |  |
Research and development expense |  |  |  |  |  | 210,418 | 189,407 | $ 156,869 |
GlaxoSmithKline plc |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Effective date of agreement | Aug. 17, 2021 |  |  |  |  |  |  |  |
Upfront payments |  | $ 700,000 |  |  |  | $ 700,000 |  |  |
Upfront payment received | $ 500,000 |  | $ 200,000 |  |  |  |  |  |
Percentage Of Development Cost |  |  |  |  |  | 0.60 |  |  |
Collaboration revenue |  |  |  |  |  | $ 62,900 | 192,100 |  |
Research and development expense |  |  |  |  |  | 14,700 | 8,800 |  |
GlaxoSmithKline plc | Maximum |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval |  |  |  |  |  | $ 1,500,000 |  |  |
Alector |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Percentage Of Development Cost |  |  |  |  |  | 0.40 |  |  |
AbbVie Biotechnology Limited |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Upfront payments |  |  |  |  | $ 205,000 | $ 205,000 |  |  |
Upfront payment received |  |  |  | $ 200,000 | 5,000 |  |  |  |
Collaboration revenue |  |  |  |  |  | 70,700 | 14,900 | $ 21,100 |
Deferred revenue |  |  |  |  |  | 46,700 | $ 117,400 |  |
Exclusive option rights exercised for each program |  |  |  |  | 250,000 |  |  |  |
AbbVie Biotechnology Limited | Subsequent Event |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  | $ 17,800
AbbVie Biotechnology Limited | Maximum |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval |  |  |  |  | $ 225,000 |  |  |  |
Innovent |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  | 0 |  |  |
Development milestone |  |  |  |  |  | 11,500 |  |  |
Sales milestone |  |  |  |  |  | $ 112,500 |  |  |

X
- Definition Collaboration and License Agreement Effective Date + References No definition available. + Details
Name: | alec_CollaborationAndLicenseAgreementEffectiveDate
Namespace Prefix: | alec_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement, additional milestone payments receivable per program. + References No definition available. + Details
Name: | alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram
Namespace Prefix: | alec_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative arrangement, milestone payments on option rights exercised per program. + References No definition available. + Details
Name: | alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram
Namespace Prefix: | alec_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative arrangement milestone payments receivable per program. + References No definition available. + Details
Name: | alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram
Namespace Prefix: | alec_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative arrangement, upfront payments. + References No definition available. + Details
Name: | alec_CollaborativeArrangementUpfrontPayments
Namespace Prefix: | alec_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development milestone. + References No definition available. + Details
Name: | alec_DevelopmentMilestone
Namespace Prefix: | alec_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of development cost. + References No definition available. + Details
Name: | alec_PercentageOfDevelopmentCost
Namespace Prefix: | alec_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sales milestone. + References No definition available. + Details
Name: | alec_SalesMilestone
Namespace Prefix: | alec_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=alec_GskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=alec_AlectorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=alec_InnoventBiologicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |